This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AP214, ZP1480
Description: AP214 (ZP1480) is a SIP-modified peptide analogue of alpha-melanocyte-stimulating hormone for the treatment of post-surgical kidney injury after major thoracic surgery. Alpha-melanocyte-stimulating hormone is a potent anti-inflammatory cytokine that inhibits many forms of inflammation including that with acute kidney injury.
Action and Zealand
In 2003, Action in-licensed Zealand's SIP technology for use with pro-opiomelanocortin derivatives. AP214 (ZP1480) is based on this license and all rights are owned by Action. Under the agreement with Action Pharma, Zealand Pharma is entitled to 10% of any paymentsreceived by Action Pharma under a third party agreement.
In May 2012, the agreement between Action and Zealand regarding the SIP technology was cancelled. As part of the agreement between Abbott and Action, Action's original licensing agreement with Zealand is cancelled, and superseded with a new agreement between Abbott and Zealand regarding the SIP technology.
Abbott and Action
In May 2012, Abbott and Action announced that they have entered into an agreement in which Abbott will acquire AP214 from Action. Under the terms of the agreement, Abbott will acquire all global rights to develop and commercialize AP214 for the prevention of AKI and other relevant indications. Abbott...See full deal structure in Biomedtracker
Partners: Zealand Pharma A/S
Additional information available to subscribers only: